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Comparison of current and estimated premorbid IQ in
schizophrenia suggests that there are subgroups with low
IQ, deteriorated IQ (DIQ), or preserved IQ and that
this is established by psychosis onset. There are no con-
trolled studies examining the trajectory of these IQ sub-
groups longitudinally or their relationship with clinical
and social outcomes. Of 129 individuals with first-
episode schizophrenia or schizoaffective disorder, 25%
showed stable low IQ, 31% showed stable IQ in the aver-
age/high range, and 44% demonstrated intellectual deteri-
oration by 10 points or more. Patients in the low and
deteriorated groups were equally impaired on tests of mem-
ory and executive function compared with the preserved av-
erage/high-IQ group and controls and showed more
negative and disorganization symptoms than the preserved
average/high-IQgroup.Sixtypatientsand27controlswere
assessed again 1 and 3 years later. There was no evidence
that those with IQ deterioration at baseline continued on
a declining cognitive trajectory or that those with preserved
average/high IQ experienced subsequent IQ decline. The
low IQ group showed no change in IQ, whereas both the
DIQ and the preserved IQ groups improved. However,
the rate of improvement of these 2 subgroups was no
greater than that of the healthy controls, suggesting that
this reflected practice effects. Both the low and the deteri-
orated groups had longer index admissions, more core neg-
ative symptoms, and worse occupational outcomes at 3
years. These data suggest that following psychosis onset,
IQ is stable and that it is IQ at psychosis onset rather
than premorbid IQ predicts a more severe illness.
Key words: schizophrenia/cognition/trajectory/
premorbid IQ/WAIS/WTAR
Introduction
Studies have found that individuals who later develop
schizophrenia have lower IQ scores than their peers prior
to the development of psychosis and as far back as
infancy.
1–7 This has been estimated as an average of
0.5 SDs below the population mean.
8 Some studies
have found that there is a decline in IQ during
adolescence,
4,9 and others found that intellectual under-
performance is greatest in those nearest to the onset of
psychosis
10,11 or that IQ deteriorates over the transition
to psychosis.
12–14
When the extent of the IQ decrement is assessed in
patients with established schizophrenia using standard
estimates of premorbid IQ, approximately 40% of
patients show a decline of 10 points or more, whereas
the remaining patients have either preserved average/
high IQ or low IQ that has not changed.
15–18 This pattern
of heterogeneity in premorbid and current IQ differences
is present at the time of the first episode
16 and, together
with the studies finding direct evidence of IQ decline,
suggests that a large subgroup of patients are on a
deteriorating cognitive trajectory at the time of
psychosis onset.
It is not known whether patients characterized in this
waycontinuetodeteriorateoncepsychosishasdeveloped
or whether those whose IQ appears to be preserved show
deterioration at a later stage. We also do not know if
these profiles are predictive of later clinical and func-
tional outcomes. There are several reasons why these
are important questions. One is that recent neuroimaging
studies have found progressive reduction in cortical gray
matter volume around the time of psychosis onset
19 and
over subsequent years.
19,20 A behavioral correlate of this
maybeprogressiveintellectualimpairment,and,ifso,the
ability to identify patients deteriorating at the behavioral
level would aid strategies aimed at cognitive enhance-
ment. Longitudinal neuropsychological studies following
the first psychotic episode tend to find no evidence of a
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768decline in cognitive functions,
21 but it remains possible
that deterioration pertains to a subgroup. Relatively
few longitudinal first-episode studies have examined
IQ alongside more specific cognitive domains
22–26 or
have assessed healthy controls in parallel to
patients.
24,27–31 None to our knowledge has examined
IQ trajectory in patients and healthy controls.
A second reason to examine IQ trajectory concerns the
concept of cognitive reserve
32 as applied to schizophre-
nia.
33 The cognitive reserve hypothesis proposes that
those with higher premorbid intellectual function are
more able to cope with the impact of neural insult either
because of higher brain structural reserve or because of
better functional capacity to use compensatory forms of
neural processing. Barnett et al
33 have proposed that in
schizophrenia, better cognitive reserve may result
in fewer psychotic symptoms either because of superior
reasoning skills or because of the ability to inhibit the
abnormal neural processing that mediates psychotic
symptoms. They also suggested that higher cognitive
reservewould resultin better functionaloutcome because
greater insight would lead to improved treatment adher-
ence. This predicts that patients with higher premorbid
IQ will have better outcomes with respect to both symp-
tom remission and social function. We previously found
that both premorbid IQ and IQ at illness onset were sig-
nificant predictors of functional outcome 4 years follow-
ing a first episode of psychosis, but the relationship with
IQ at onset was stronger.
34 van Winkel et al,
35 on the
otherhand,foundthatthereversewastrue;ie,premorbid
IQ but not IQ at the first psychotic episode predicted
10-year functional outcome. Thus, the latter study sup-
ports the cognitive reserve hypothesis, but our findings
suggest that it is the IQ measured after the development
of psychosis is more important for prognosis.
The current study investigated the stability of IQ
following the first psychotic episode to establish whether
there are further changes and whether different IQ trajec-
tories have an impact on symptoms and social outcomes.
Initially, we assessed patients to establish whether our
previous finding of different premorbid current IQ
subgroups at psychosis onset
16 could be demonstrated
in a different first-episode group. We then examined
patients in 3 IQ categories, preserved average/high
IQ, low IQ, and deteriorated IQ (DIQ), at 2 further
time points over the following 3 years. We compared
IQ trajectory with that of verbal memory and executive
function because these are thought to be specifically
impaired in schizophrenia and may be more relevant
to outcome. We also included potential moderating
factors in our analysis, including age of onset of psycho-
sis, duration of untreated psychosis, premorbid social
adjustment (PSA), insight, and adherence to medica-
tion. Finally, we compared our neuropsychological
findings in patients with healthy controls tested at the
same time points.
Method
Participants
Onehundredtwenty-ninepatientswithafirst-episodepsy-
chosis (108 schizophrenia and 21 schizoaffective) were
recruited into the West London First Episode Psychosis
Study. Patients eligible for the study were screened with
the World Health Organization Psychosis Screen
36 and
were recruited if they were between 16 and 60 years old,
presenting for the first time with a psychotic illness, and
had received no more than 12 weeks of antipsychotic
medication. The diagnosis was ascertained by means of
a structured interview, the diagnostic module of the
DiagnosisInterviewforPsychosis,
37whichincludesitems
from the Operational Criteria Checklist for Psychosis
(OPCRIT)
38 and the World Health Organization Sched-
ulesforClinicalAssessmentinNeuropsychiatry.
39Acom-
puterized algorithm generates diagnoses under several
classificationsystems,includingDiagnosticandStatistical
Manual of Mental Disorders (DSM)-IIIR and Interna-
tionalClassificationofDiseases-10(DSM-IIIRdiagnoses
werethencheckedagainstDSM-IVcriteriausingOPCRIT
for Windows [http://sgdp.iop.kcl.ac.uk/opcrit/]).
Five patients were medication free, 5 prescribed
first-generation antipsychotics, 118 prescribed second-
generation antipsychotics, and 1 prescribed a combina-
tion of first- and second-generation antipsychotics.
One hundred twenty healthy controls were recruited
from the same catchment area that the patients derived
from, with the exclusion criterion of a history of psychi-
atric illness in themselves or first-degree relatives.
Demographic information on the control group and
patient subgroups is shown in table 1.
Seventy-eight patients (61 schizophrenia and 17 schiz-
oaffective) were followed up approximately 1 year after
the initial assessment and 60 (48 schizophrenia and
12 schizoaffective) 1 and 3 years after the initial assess-
ment; 27 controls were assessed on all 3 occasions. The
mean number of weeks between baseline and second
assessment was 59.22 (17.23) for patients and 59.40
(32.37) for controls and between baseline and third
assessment was 143.42 (44.97) for patients and 130.39
(41.54) for controls. Diagnostic assessments were
conducted at each time point; the diagnosis reached
was that from the most recent assessment, which was
consistent in those assessed at both the 1- and the
3-year follow-up time points. Permission to conduct
the study was obtained from appropriate research ethics
committees. Participants gave written informed consent
and were paid an honorarium for their time.
Clinical Assessments
The range and severity of psychotic symptoms were
assessed using the Scales for the Assessment of Positive
andNegativeSymptoms,
40andscoresforthe3symptom-
derived syndromes of schizophrenia (negative, positive,
IQ Trajectory in First-Episode Psychosis
769and disorganization) were calculated.
41 Social function
wasassessedusingtheSocialFunctionScale(SFS)
42where
individualsratetheirabilitiesin7areasincludingemploy-
ment or occupational activity, and an overall score is also
calculated. Affective symptoms were measured by the
Hamilton Rating Scale for Depression
43 and the Young
Mania Rating Scale.
44 To establish the timing of onset
of the psychotic illness, the Nottingham Onset Scale
45
wasused.Thelengthofindexadmissionwasalsoobtained
from clinical notes, scored as 0 where treatment was as an
outpatient.PremorbidfunctionwasassessedwiththePSA
scale.
46InsightwasassessedusingtheSchedulefortheAs-
sessment of Insight.
47 Adherence with medication was
assessed using the Compliance Rating Scale.
48
Cognitive Assessments
Current IQ was measured using a short form of the
Wechsler Adult Intelligence Scale (WAIS) III
49
composed of 4 subtests: information, arithmetic, block
design, and digit symbol and developed for use in schizo-
phrenia.
50 Prorated full-scale IQ (FSIQ) was calculated.
Premorbid IQ was estimated using the Weschler Test of
Adult Reading (WTAR).
51
Immediateverbalmemoryandlearningweremeasured
using the Rey Auditory Verbal Learning Task
52 in which
subjects are asked to read a list of 15 nouns. Immediate
recall of the words was recorded as immediate memory
and learning as the sum of words recalled over 5 trials,
with the list being reread between each trial.
Other tests of memory and executive function were
taken from the Cambridge Automated Neuropsycholog-
ical Test Battery
53 as follows: working memory span,
takenfromthespatialspantask.Thistestofforwardspa-
tial span is akin to the Corsi block test. The maximum
number of consecutively presented spatial locations
that were successfully recalled was measured. Working
memory manipulation, taken from the spatial working
memory task. This is a self-ordered search task whereby
participants need to recall where previous ‘‘tokens’’ were
found from a random array of ‘‘boxes’’ in order to max-
imize success at finding subsequent tokens. The number
of search errors was measured. Planning, this is analo-
goustotheTowerofLondontask.Inaseriesofproblems
varyingin difficulty,subjects planand execute asequence
of moves of stimuli in a visual array to match a goal ar-
ray.Thenumberofmovesrequiredrangefrom2to5with
12 trials in total. The total number of perfect solutions
was measured.
IQ Subgroups
The patient group was divided according to current and
premorbid IQ. low IQ: WAIS and WTAR <90 and
WTAR within 10 points of WAIS, preserved IQ:
WTAR and WAIS  90 and a WTAR within 10 points
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V. C. Leeson et al.of WAIS, and DIQ: WTAR greater than WAIS by more
than 10 points.
Analysis
Data were analyzed using SPSS v15.0. Duration of un-
treated psychosis (DUP) was non-normally distributed
and log transformed before analysis. Categorical data
were analyzed using chi-square and continuous data us-
ing one-way analysis of variance (ANOVA). Linear
mixed models were used to assess change over time
and between groups separately for each cognitive mea-
sure and IQ. This approach allows inclusion of all cases,
including those with missing data points, and thus makes
use of incomplete longitudinal data. Because many
patients were asymptomatic at follow-up, the symptoms
scores were not normally distributed nor could they be
transformed to return them to normal distribution.
Therefore, Friedman’s nonparametric ANOVA by ranks
was used to assess change over time in symptoms. To
compare psychotic syndrome scores and affective symp-
tom scores between groups at 3-year follow-up, Kruskal-
Wallis nonparametric ANOVA was used. Length of in-
dex admission, compliance, and insight scores were also
non-normally distributed and could not be returned to
normal by transformation, so were also analyzed using
Kruskal-Wallis nonparametric ANOVA.
Results
Table 1 shows the demographic and neuropsychological
measures at the initial assessment for controls and IQ
subgroups, which were matched for age and sex. There
were no differences between preserved IQ and control
groups on premorbid and current IQ. These 2 groups
were also similar on verbal immediate memory, spatial
span, and planning, but the controls were better on spa-
tial working memory manipulation and verbal learning.
The mean premorbid IQ of the DIQ group was in the
normal range, although this was significantly less than
the preserved IQ group. The currentIQ of the DIQ group
indicatedthat IQin thisgrouphad declined to thelevel of
thelowIQgroupatbaseline.TheDIQandlowIQgroups
were equally worse on all neuropsychological tests com-
pared with controls.
Table 2 shows that, within the schizophrenia
subgroups, there were no differences in age at onset,
DUP, PSA, and affective or positive psychotic symptoms
at presentation. The preserved IQ group had less severe
negative and disorganization symptoms compared with
the other 2 groups, which were not different.
Follow-Up
To determine whether individuals who were successfully
followed up were representative of the whole baseline
group, we compared those who completed all 3 assess-
ments with those who were assessed at baseline only
on age, sex, years of education, and premorbid and
current IQ; controls and patient IQ subgroups were
examined separately. Completers vs noncompleters
from the control, low IQ, and DIQ groups did not signif-
icantly differ on these measures. The preserved IQ group
didnotdifferonpremorbidIQ,currentIQ,oragebutdid
differ on sex, with female patients being overrepresented
in the follow-up group, and years of education, with
those who were successfully followed up having more
Table 2. Comparison of First-Episode Measures of Clinical Functioning in the Patient IQ Subgroups. Group Means are Presented With
SDs in Parenthesis
Low
IQ Subgroup
DIQ
Subgroup
Preserved
IQ Subgroup Statistic Post Hoc
Days between start of
treatment and
neuropsychological assessment
59.06 (51.56) 56.65 (72.87) 62.73 (40.37) F2,126 = 0.12, P = .885
DUP weeks
a 18.22 (23.56) 56.54 (107.52) 49.95 (92.46) F2,128 = 2.16, P = .120
Premorbid social adjustment 21.80 (8.24) 19.89 (6.86) 20.67 (8.20) F2,104 = 0.50, P = .610
Age of onset 23.88 (6.40) 24.16 (7.21) 26.38 (9.24) F2,128 = 1.26, P = .288
Negative syndrome score 0.41 (0.28) 0.40 (0.25) 0.23 (0.22) F2,128 = 6.79, P = .002 PIQ < LIQ, DIQ
Core negative symptoms 4.69 (3.61) 4.07 (3.27) 2.33 (2.99) F2,128 = 5.34, P = .006 PIQ < LIQ, DIQ
Positive syndrome score 0.80 (0.20) 0.73 (0.23) 0.69 (0.21) F2,128 = 2.32, P = .102
Disorganization syndrome score 0.48 (0.31) 0.50 (0.32) 0.32 (0.26) F2,128 = 4.69, P = .011 PIQ < LIQ, DIQ
Hamilton Depression Rating Scale 12.06 (7.31) 14.56 (8.97) 12.75 (8.96) F2,127 = 1.01, P = .368
Young Mania Rating Scale 7.73 (7.24) 10.16 (11.73) 7.58 (10.01) F2,126 = 0.94, P = .393
Note: DIQ, deteriorated IQ; DUP, duration of untreated psychosis.
aAnalysis performed on log-transformed score.
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IQ Trajectory in First-Episode Psychosisyears of education than those who were not. The group
characteristics of those who were included in the follow-
up analyses and comparisons of completers vs noncomp-
leters are provided in the Supplementary table.
Cognitive Change
Both unstructured and autoregressive linear mixed mod-
els were used to assess change over time across all groups
(table 3). The autoregressive model was a better fit in all
cases according to Schwarz’s Bayesian Criterion (BIC)
and thus are reported here.
Intelligence Quotient. Overall, there was a significant
improvement over time in IQ, and there was a significant
interaction between group and time. This interaction
reflected less change between baseline and 3-year
follow-up in the low IQ group than the other groups.
Memory and Executive Function. Immediate verbal
memory, verbal learning, and spatial working memory
spanallimprovedsignificantlyovertime,butnoneshowed
a significant interaction between time and group. Perfor-
manceonspatialworkingmemorymanipulationandplan-
ningdidnotchangeovertime,andtherewasnosignificant
interaction between time and group for either.
Clinical and Functional Outcome
The IQ subgroups that completed all 3 assessments were
compared on the trajectory of their symptoms. All 3
groups improved on positive, negative, and disorganiza-
tionsymptoms; depression;andmania ratingswith the ex-
ception of the preserved IQ group, which did not show an
improvement in the negative syndrome score (table 4).
At 3-year follow-up, there were no significant differen-
cesbetweenthegroupsforthepositive(v
2=0.10, P= .755)
or disorganization (v
2 = 0.17, P = .677) syndromes. There
wasanonsignificanttrendfor thenegative syndrometobe
different (v
2 = 2.99, P = .084), and when the analysis was
restricted to the core negative symptoms of affective flat-
tening and alogia, there was a significant difference be-
tween the groups (v
2 = 6.63, P = .036) reflecting more
symptoms in the DIQ than in the preserved IQ group
(v
2 = 6.44, P = .011). There was no difference between
the groups in terms of insight (v
2 = 0.52, P = .772) or med-
icationadherence (v
2 = 0.53, P = .771) at 3-year follow-up.
Therewasnodifferencebetweenthe3patientgroupsat3
yearsintotalSFSscore(F2,59=0.42,P=.657),buttherewas
asignificantdifferenceintheemployment/occupationSFS
subscale (F2,59 = 4.22, P = .019), and post hoc analyses
showed a significant difference between the preserved IQ
and DIQ groups (P = .029), trend level difference between
the preserved IQ and low IQ groups (P = .054),andnodif-
ferencebetween the low IQandDIQ groups(P = .978). At
follow-up, 62% ofthe preserved IQ group were engaged in
work or study compared with 30% in the DIQ group and
33% in thelow IQ group.Thegroupsdifferedsignificantly
in length of index admission (v
2 = 6.05, P = .049), and
pairwise comparisons showed that the low IQ and DIQ
groupsdidnotdiffer(v
2=0.803,P=.370),butthepatients
inthepreservedIQgrouphadshorteradmissionscompared
withthelowIQgroup(v
2= 5.43,P= .020)andDIQgroup
(v
2 = 3.27, P = .071) at a trend level of significance.
Table 3. Findings From First-Order Autoregressive Linear Mixed Models Comparing Cognitive Measures in the Controls and low IQ
(LIQ), deteriorated IQ, and preserved IQ (PIQ) Groups. Effects at P < .01 Were Considered Significant. Where Interactions Were
Significant, Those Time and Group Points That Significantly Differed From the Whole Model Are Reported (n = 129)
Measure
Group
Difference
Change Over
Time (All Groups)
Coefﬁcients of
Signiﬁcant
Differences
Time By
Group
Interaction
Coefﬁcient of
Signiﬁcant
Differences
Current IQ F3,272.8 = 109.66,
P < .001
F2,262.9 = 13.00,
P < .001
Baseline:  8.89;
1 year:  4.73;
3 years: reference
F6,262.4 = 3.22,
P = .005
LIQ baseline: 7.23;
P = .029; all others NS
Immediate verbal
memory
F3,247.0 = 27.09,
P < .001
F2,332.4 = 4.99,
P = .007
Baseline:  0.85;
1 year:  0.87;
3 years: reference
F6,227.2 = 0.75,
P = .614
n/a
Verbal learning F3,263.5 = 62.44,
P < .001
F2,298.5 = 13.20,
P = .007
Baseline:  5.90;
1 year:  7.18;
3 years: reference
F6,296.1 = 1.22,
P = .300
n/a
Spatial working
memory span
F3,246.7 = 26.52,
P < .001
F2,283.8 = 6.73,
P = .001
Baseline:  0.41;
1 year:  0.31;
3 years: reference
F6,281.9 = 1.11,
P = .350
n/a
Spatial working
memory manipulation
F3,277.7 = 21.77,
P < .001
F2,188.3 = 2.57,
P = .079
n/a F6,188.3 = 1.34,
P = .243
n/a
Planning F3,235.2 = 20.18,
P < .001
F2,314.17 = 3.59,
P = .029
n/a F6,312.97 = 1.77,
P = .104
n/a
Note: NS, non-significant; n/a, not applicable.
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To investigate whether premorbid IQ or IQ decline in the
DIQ group determined outcome, we reanalyzed the data,
including only those patients in the DIQ group with
WTAR  90 (n = 35 in study and n = 19 completed
follow-up). Examining the trajectory of WAIS IQ over
the 3 time points, there remained a significant interaction
between time and group (F6,239.6 = 3.71, P = .002), with
the low IQ group showing less improvement over time.
Figure 1 shows the IQ trajectory of those controls and
IQ subgroups that completed all 3 assessments, with
only those in the DIQ group with average/high premor-
bid IQ included. In terms of outcome, the groups
remained significantly different on SFS employment/oc-
cupation score (F2,51 = 4.93, P = .011); 32% of this subset
of the DIQ group were engaged in work or study at
3 years. There was a nonsignificant trend for the length
of index admission to differ among the groups (v
2 = 5.24,
P = .073), with the preserved IQ group being shorter than
low IQ group and the DIQ group being intermediate be-
tween the two. There were no differences in core negative
symptoms at 3 years (v
2 = 2.75, P = .253).
To further investigate the differential impact of cur-
rent IQ and premorbid IQ on cognitive and clinical
outcomes, we also examined the correlation between
both IQ scores and measures of outcome across all
patients, regardless of their IQ subgroup. Collinearity
between the premorbid and current IQ scores means
that if one is a strong predictor of a particular outcome
measure, the other is likelyto alsopredict thatsame out-
comemeasure.Nevertheless,currentIQcorrelatedmore
highly with outcome than premorbid IQ. All 3-year cog-
nitive measures, SFS employment/occupation, core neg-
ative symptoms, and length of index admission, were
correlated with current IQ at P < .01. Only immediate
verbal memory, verbal learning, and planning were
correlated with premorbid IQ at P < .01. Table 5 shows
the correlations.
Table 4. Results of Analyses of Changein Psychosis andAffective Symptoms Over Time in the lowIQ (LIQ), deteriorated IQ (DIQ), and
preserved IQ (PIQ) Groups (n = 60)
Measure LIQ (n = 12) DIQ (n = 27) PIQ (n = 21)
Negative syndrome score v
2 = 10.31, P = .006 v
2 = 8.77, P = .001 v
2 = 2.98, P = .225
Positive syndrome score v
2 = 11.70, P = .003 v
2 = 22.18, P < .001 v
2 = 26.43, P < .001
Disorganization syndrome score v
2 = 16.29, P < .001 v
2 = 34.28, P < .001 v
2 = 19.77, P < .001
Hamilton Depression Rating Scale v
2 = 14.00, P = .001 v
2 = 7.70, P = .021 v
2 = 26.00, P < .001
Young Mania Rating Scale v
2 = 5.82, P = .05 v
2 = 21.88, P < .001 v
2 = 19.00, P < .001
Fig. 1. Estimated Premorbid IQ Using Weschler Test of Adult
Reading (WTAR) and 3-Year Trajectory of Current IQ in the
Controls and Low IQ, Deteriorated IQ (WTAR ‡90 Only), and
preservedIQSubgroups.WAIS,WechslerAdultIntelligenceScale.
Table 5. Pearson’s r or Spearman’s rho
Estimated
Premorbid IQ
Baseline
Current IQ
Immediate verbal memory 0.50* 0.55*
Verbal learning 0.45* 0.54*
Spatial working memory span 0.30** 0.45*
Spatial working memory
manipulation (error score)
 0.20  0.38***
Planning 0.37** 0.46*
Negative syndrome score
a  0.27**  0.25
(Core negative symptoms only)
a  0.26**  0.33***
Positive syndrome score
a 0.06  0.05
Disorganization syndrome score
a  0.10  0.07
Hamilton Depression Rating Scale
a 0.15 0.09
Young Mania Rating Scale
a  0.05  0.20
Medication adherence
a 0.15 0.14
Insight
a 0.24 0.19
Length of index admission
a  0.33**  0.36***
SFS overall score 0.14 0.16
SFS employment/occupation
subscale score
0.32** 0.40***
Note: SFS, Social Function Scale.
aCorrelations between premorbidor current IQ at baseline and
outcome measures in all patients who completed 3 assessments
(n = 60).
**P < .05, ***P < .01, and *P < .001.
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In this study, we replicated our previous finding of
heterogeneity in the relationship between premorbid and
current IQ
16 in a different group of patients with first-epi-
sode schizophrenia or schizoaffective disorder. Thus, 44%
of patients showed a 10-point or greater decline in IQ,
whereas the IQ of the remaining patients was stable up to
the first psychotic episode, with 25% having low IQ values
andtheremainingpatientshavingpreservedIQinthenor-
mal range or higher. This finding is also in agreement with
other studies examining patients with established schizo-
phrenia.
15,17,18 At first episode, the preserved IQ group
had less severe negative and disorganization symptoms
than the other 2 groups, which were not different, but no
other clinical feature distinguished the groups, including
thelevelofpremorbidsocialfunction,ageatonset,duration
ofuntreated psychosis, and severity ofaffective orpositive
psychotic symptoms.
Duringthe 3yearsfollowingpsychosisonset,therewas
no evidence that those with IQ deterioration continued
on a declining cognitive trajectory or that those with pre-
served average/high IQ experienced IQ decline following
onset. The low IQ group showed no statistically signifi-
cant change in IQ, whereas both the DIQ and the pre-
served IQ groups improved. However, the rate of
improvement of these 2 subgroups was no greater than
that of the healthy controls, suggesting that this reflected
practice effects. These findings support previous con-
trolled studies that showed improvement in IQ following
psychosis onset that was equal to or less than that of
healthy controls
23,24 and suggests that the improvement
in IQ after the first episode seen in uncontrolled studies is
nonspecific.
22,25,26
To our knowledge, only 1 other study has compared
estimates of premorbid IQ with IQ trajectory following
psychosis onset, and this did not include healthy con-
trols.
54 In this study, patients were dichotomized accord-
ing to estimated premorbid IQ; the lower premorbid IQ
groupshowednochangeinIQwhenassessedbothatfirst
episode and at 6–14 years later, whereas the higher pre-
morbid IQ group showed a decline in IQ at first episode,
which subsequently improved to premorbid levels. In our
study, by separating patients with and without evidence
of IQ decline at first episode,
18 we showed that, although
patientswith IQdeclineimprovedbetween firstpsychotic
episode and later follow-up, this was no greater than that
seen in healthy controls. We could find no evidence that
even those patients with relatively high premorbid IQ
(>90) who had declined by psychosis onset subsequently
improved to premorbid levels.
The same group
35 also reported that IQ at psychosis
onset did not predict functional outcome, whereas
premorbid IQ was a significant predictor but only
when adjusted for the confounding effects of DUP,
gender, and age of onset. We have previously shown in
a different group of first-episode patients that both pre-
morbid IQ and IQ at first episode predicted 4-year func-
tional outcome but that IQ at onset was the stronger
predictor, and neither findings were confounded.
34 In
the current study, we replicated this finding in a new
group of patients by examining the level of correlation
between outcome measures and measures of premorbid
and current IQ at baseline for the group of patients
who had 3 assessments. Because premorbid and current
IQ are intercorrelated, it is impossible to completely tease
apart the contribution of these 2 measures; however, the
results suggest that current baseline IQ was a better pre-
dictor of outcome, being more highly correlated with sev-
eral cognitive measures, core negative symptoms, and
occupational functioning at 3-year follow-up, as well
as the length of index admission. The current study
extends these findings by showing that those with pre-
served IQ in the average/high range had better outcomes
than the other 2 groups in that they had less disorgani-
zation and negative symptoms at onset, shorter index
admissions, less core negative symptoms, and better oc-
cupational outcome at 3 years. The group that showed
adeclineinIQcloselyresembledthelowIQgroupintheir
currentIQatfirstepisode,lengthofindexadmission, and
occupational function at 3 years in addition to showing
more core negative symptoms than the average/high-IQ
group. Within the DIQ group, even those who declined
from average/high levels had as poor an occupational
outcome as those with lower premorbid IQ. These results
suggest that it was not premorbid IQ but the IQ that the
DIQ group arrived at by the time of the first psychotic
episode that predicted a more severe illness.
These findings also have implications for the cognitive
reserve hypothesis, which proposes that the higher the
premorbidcognitiveability,themoreresilientindividuals
are to the impact of cerebral dysfunction.
32,33 Our find-
ingssuggestthatinschizophrenia,therearesomepatients
whobenefitfromcognitivereservebecausetheyhavepre-
morbid ability in the average/high range, which remains
stable following the onset of psychosis. However, there
are others with similar levels of premorbid ability who
undergo a decline in cognitive ability sufficient to cause
diminished cognitive reserve and worse outcome. We
were unable to identify any predictive measures that
could distinguish these 2 groups, such as age at onset, du-
ration of untreated psychosis, and PSA. Thus, the eluci-
dation of factors that confer vulnerability to cognitive
change during the development of psychosis requires
furtherstudybecausethisgroupmaybeparticularlyame-
nable to intervention if detected early enough.
The current findings and those of others
21 have failed
to elucidate possible cognitive correlates of the continu-
ing reductions in gray matter volume following psychosis
onset seen in neuroimaging studies.
19,20 Gray matter vol-
ume loss early in the illness is clearly of clinical relevance
because Cahn et al
55 found that those with the greatest
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symptomsandpoorestfunctionaloutcome.Oneexplana-
tion is that the structural changes giving rise to cognitive
impairment have occurred by the time of presentation
with psychosis, and therefore, the neural context for
poor outcome is already established for some patients
at this stage. Although the continuing volumetric reduc-
tions detected on MRI could represent the manifestation
of these changes, their functional consequences may al-
ready have been declared. Our data support the view
thatthe abilitytodetect patientswith adeterioratingcog-
nitive course very early in the development of psychosis,
at the ultra high-risk stage, will be important for neuro-
protective strategies in schizophrenia.
56–58
At baseline, the low IQ and DIQ groups performed
equivalently on tests of verbal learning and memory,
working memory, and planning and significantly worse
than the controls and preserved IQ groups. These
findings are compatible with those of Kremen et al
17
who found that subgroups of schizophrenia patients
withpreservedIQandDIQ,matchedoncurrentIQ,dem-
onstrated similar neuropsychological performance. Our
DIQ group had comparable current IQ to our low IQ
group,andbecauseperformance onallcognitivemeasure
was the same in these 2 patient groups, our findings
support their conclusion that in schizophrenia; current
neuropsychological performance is a function of current
IQ rather than prior intellectual trajectory.
At follow-up, there was evidence of improvement over
time on verbal immediate memory and learning and
spatial working memory span, but this was equivalent
across IQ subgroups and controls. Improvement in the
controls indicated that practice enhanced performance,
and this finding emphasizes the importance of a compar-
isoncontrolgroupwhenassessingchangeinperformance
of specific cognitive functions over time in keeping with
a study of improvement in cognition following treatment
with antipsychotic medication.
29 Despite performing bet-
terthanthelowIQandDIQgroups,thosewithpreserved
IQ were significantly impaired compared with controls
on verbal learning and spatial working memory manip-
ulation. We and others have previously found that pre-
served IQ subgroups have impaired executive function
and verbal memory.
16–18,59 However, when IQ and spe-
cific measures of memory and executive function were
compared as predictors of outcome, we previously found
that only IQ consistently predicted functional outcome
whether measured as a premorbid estimate or at 3
time points over 4 years following onset.
34
A limitation of this study is the use of an indirect
measure of premorbid IQ. There are many studies sub-
stantiating the use of tests of irregular word pronuncia-
tion in normal volunteers and in a variety of
neuropsychiatric disorders.
60–63 The majority of studies
comparing patients with chronic stable or acutely symp-
tomatic schizophrenia with matched controls and other
patient groups have found these tests to be a valid
measure of premorbid IQ,
64,65 and other studies have
found estimated IQ to be stable over time.
66,67 Neverthe-
less, the use of tests of irregular word pronunciation in
schizophrenia has been criticized on the grounds that
the disorder itself may be related to impairment in verbal
ability, thus causing IQ to be underestimated.
68 Against
this are studies that have found that current vocabulary
approximates direct measures of premorbid IQ in
schizophrenia.
69,70 Conversely, another criticism is that
irregularword-readingtasksoverestimateIQatthelower
FSIQ range, givinga spurious impression of IQ decline.
70
We do not think that this explains our findings because
25% of patients were classified as having low current IQ,
characterized as equivalent estimated premorbid and
current IQ. Another limitation is that, although we
completed all assessments for 60 patients when these
were divided into IQ groups, the numbers were inevitably
rather small. Our findings therefore require further study
in larger high-risk groups where direct measures of
premorbid IQ can be ascertained.
Supplementary Material
Supplementary table is available at http://schizophrenia-
bulletin.oxfordjournals.org.
Funding
Wellcome Trust (064607).
Acknowledgments
Weare grateful to Isobel Harrison and Stan Mutsatsa for
clinical assessments and the consultants and nurses of
West London and South West London and St
George’s Mental Health National Health Service
Trusts for greatly facilitating the study. E.M.J. and
V.C.L. acknowledge support from the Raymond Way
Fund. T.R.E.B. has acted as a consultant for Servier,
Johnson & Johnson, and Bristol-Myers Squibb. The
other authors have no biomedical financial interests or
potential conflicts of interest.
References
1. David AS, Malmberg S, Brandt L, Allebeck P, Lewis G. IQ
and risk for schizophrenia: a population-based cohort study.
Psychol Med. 1997;27:1311–1323.
2. Davidson M, Reichenberg A, Rabinowitz J, et al. Behavioral
and intellectual markers for Schizophrenia in apparently
healthy male adolescents. Am J Psychiatr. 1999;156:1328–
1335.
3. Jones P, Murray R, Jones P, Rodgers B, Marmot M. Child
developmental risk factors for adult schizophrenia in the
British 1946 birth cohort. Lancet. 1994;344:1398–1402.
775
IQ Trajectory in First-Episode Psychosis4. Kremen WS, Buka SL, Seidman LJ, et al. IQ decline during
childhood and adult psychotic symptoms in a community
sample: a 19-year longitudinal study. Am J Psychiatr.
1998;155:672–677.
5. Cannon TD, Bearden CE, Hollister JM, et al. Childhood
cognitive functioning in schizophrenia patients and their
unaffected siblings: a prospective cohort study. Schizophr
Bull. 2000;26:379–393.
6. Zammit S, Allebeck P, David AS, et al. A longitudinal study
of premorbid IQ score and risk of developing schizophrenia,
bipolar disorder, severe depression, and other nonaffective
psychoses. Arch Gen Psychiatr. 2004;61:354–360.
7. Bilder RM, Reiter G, Bates JA, et al. Cognitive development
in schizophrenia: follow back from first episode. J Clin Exp
Neuropsychol. 2006;28:270–282.
8. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in
schizophrenia: a meta-analytic review. Am J Psychiatr.
2008;165:579–587.
9. Fuller R, Nopoulos P, Arndt S, et al. Longitudinal assess-
ment of premorbid cognitive functioning in patients with
schizophrenia through examination of standardized scholas-
tic test performance. Am J Psychiatr. 2002;159:1183–1189.
10. Rabinowitz J, Reichenberg A, Weiser M, et al. Cognitive and
behavioural functioning in men with schizophrenia both
before and shortly after first admission to hospital.
Cross-sectional analysis. Br J Psychiatr. 2000;177:26–32.
11. Gunnell D, Harrison G, Rasmussen F, Fouskakis D,
Tynelius P. Associations between premorbid intellectual per-
formance, early-life exposures and early-onset schizophrenia:
cohort study. Br J Psychiatr. 2002;181:298–305.
12. Cosway R, Byrne M, Clafferty R, et al. Neuropsychological
change in young people at high risk for schizophrenia: results
from the first two neuropsychological assessments of the Edin-
burgh High Risk Study. Psychol Med. 2000;30:1111–1121.
13. Caspi A, Reichenberg A, Weiser M, et al. Cognitive perfor-
mance in schizophrenia patients assessed before and follow-
ing the first psychotic episode. Schizophr Res. 2003;65:87–94.
14. Lencz T, Smith CW, McLaughlin D, et al. Generalized and
specific neurocognitive deficits in prodromal schizophrenia.
Biol Psychiatr. 2006;59:863–871.
15. Badcock JC, Dragovic M, Waters FAV, Jablensky A. Dimen-
sions of intelligence in schizophrenia: evidence from patients
with preserved, deteriorated and compromised intellect.
J Psychiatr Res. 2005;39:11–19.
16. Joyce EM, Hutton SB, Mutsatsa SH, Barnes TRE. Cognitive
heterogeneity in first-episode schizophrenia. Br J Psychiatr.
2005;187:516–522.
17. Kremen WS, Seidman LJ, Faraone SV, Tsuang MT. IQ
decline in cross-sectional studies of schizophrenia: methodol-
ogy and interpretation. Psychiatry Res. 2008;158:181–194.
18. Weickert TW, Goldberg TE, Gold JM, et al. Cognitive
impairments in patients with schizophrenia displaying
preserved and compromised intellect. Arch Gen Psychiatr.
2000;57:907–913.
19. Sun D, Phillips L, Velakoulis D, et al. Progressive brain struc-
tural changes mapped as psychosis develops in ‘at risk’
individuals. Schizophr Res. 2009;108:85–92.
20. Cahn W, Rais M, Stigter FP, et al. Psychosis and brain
volume changes during the first five years of schizophrenia.
Eur Neuropsychopharmacol. 2009;19:147–151.
21. Szoke A, Trandafir A, Dupont ME, et al. Longitudinal stud-
ies of cognition in schizophrenia: meta-analysis. Br J
Psychiatr. 2008;192:248–257.
22. GoldS,ArndtS,NopoulosP,O’LearyDS,AndreasenNC.Lon-
gitudinal study of cognitive function in first-episode and recent-
onset schizophrenia. Am J Psychiatr. 1999;156:1342–1348.
23. Hoff AL, Svetina C, Shields G, Stewart J, DeLisi LE. Ten
year longitudinal study of neuropsychological functioning
subsequent to a first episode of schizophrenia. Schizophr
Res. 2005;78:27–34.
24. Frangou S, Hadjulis M, Vourdas A. The Maudsley early
onset schizophrenia study: cognitive function over a 4-year
follow-up period. Schizophr Bull. 2008;34:52–59.
25. The Scottish Schizophrenia Research Group.The Scottish
first episode schizophrenia study V. One-year follow-up. Br
J Psychiatr. 1988;152:470–476.
26. Townsend LA, Norman RMG, Malla AK, Rychlo AD,
Ahmed RR. Changes in cognitive functioning following com-
prehensive treatment for first episode patients with schizo-
phrenia spectrum disorders. Psychiatry Res. 2002;113:69–81.
27. Albus M, Hubmann W, Mohr F, et al. Neurocognitive func-
tioning in patients with first-episode schizophrenia: results of
a prospective 5-year follow-up study. Eur Arch Psychiatry
Clin Neurosci. 2006;256:442–451.
28. Hill SK, Keshavan MS, Thase ME, Sweeney JA. Neuropsy-
chological dysfunction in antipsychotic-naive first-episode
unipolar psychotic depression. Am J Psychiatr. 2004;161:
996–1003.
29. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive
improvement after treatment with second-generation antipsy-
chotic medications in first-episode schizophrenia: is it a
practice effect? Arch Gen Psychiatr. 2007;64:1115–1122.
30. Addington J, Saeedi H, Addington D. The course of cognitive
functioning in first episode psychosis: changes over time and
impact on outcome. Schizophr Res. 2005;78:35–43.
31. Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R,
et al. Neurocognitive effectiveness of haloperidol, risperidone,
and olanzapine in first-episode psychosis: a randomized,
controlled 1-year follow-up comparison. JC l i nP s y c h i a t r .
2009;70:717–729.
32. Stern Y. What is cognitive reserve? Theory and research
application of the reserve concept. J Int Neuropsychol Soc.
2002;8:448–460.
33. Barnett JH, Salmond CH, Jones PB, Sahakian BJ. Cognitive
reserve in neuropsychiatry. Psychol Med. 2006;36:1053–1064.
34. Leeson VC, Barnes TRE, Hutton SB, Ron MA, Joyce EM.
IQ as a predictor of functional outcome in schizophrenia:
a longitudinal, four-year study of first-episode psychosis.
Schizophr Res. 2009;107:55–60.
35. van Winkel R, Myin-Germeys I, De Hert M, et al. The
association between cognition and functional outcome in
first-episode patients with schizophrenia: mystery resolved?
Acta Psychiatr Scand. 2007;116:119–124.
36. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia:
manifestations, incidence and course in different cultures. A
World Health Organization ten-country study. Psychol Med
Monogr Suppl. 1992;20:1–97.
37. Jablensky A,McGrath J, Herrman H, et al. Psychotic disorders
inurbanareas:anoverviewoftheStudyonLowPrevalenceDis-
orders. Aust N Z J Psychiatr. 2000;34:221–236.
38. McGuffin P, Farmer A, Harvey I. A polydiagnostic applica-
tion of operational criteria in studies of psychotic illness.
Development and reliability of the OPCRIT system. Arch
Gen Psychiatr. 1991;48:764–770.
776
V. C. Leeson et al.39. Wing JK, Babor T, Brugha T, et al. SCAN. Schedules for
clinical assessment in neuropsychiatry. Arch Gen Psychiatr.
1990;47:589–593.
40. Andreasen N. Methods for assessing positive and negative
symptoms. Basel, Switzerland: Karger; 1990.
41. Liddle PF, Barnes TRE. Syndromes of chronic schizophrenia.
Br J Psychiatr. 1990;157:558–561.
42. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S.
The Social Functioning Scale. The development and valida-
tion of a new scale of social adjustment for use in family in-
tervention programmes with schizophrenic patients. Br J
Psychiatr. 1990;157:853–859.
43. Hamilton M. A rating scale for depression. J Neurol Neuro-
surg Psychiatr. 1960;23:56–62.
44. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale
for mania: reliability, validity and sensitivity. Br J Psychiatr.
1978;133:429–435.
45. Singh SP, Cooper JE, Fisher HL, et al. Determining the chro-
nology and components of psychosis onset: the Nottingham
Onset Schedule (NOS). Schizophr Res. 2005;80:117–130.
46. Foerster A, Lewis S, Owen M, Murray RM. Pre-morbid
adjustment and personality in psychosis: effects of sex and
diagnosis. Br J Psychiatr. 1991;158:171–176.
47. David AS. Insight and psychosis. Br J Psychiatr. 1990;156:
798–808.
48. Hayward P, Chan N, Kemp R, Youle S, David AS. Medication
self management: a preliminary report on an intervention to im-
prove medication compliance. J Ment Health. 1995;4:511–517.
49. Wechsler D. Wechsler Adult Intelligence Scale-3rd Edition
(WAIS-3). San Antonio, TX: Harcourt Assessment; 1997.
50. Blyler CR, Gold JM, Iannone VN, Buchanan RW. Short
form of the WAIS-III for use with patients with schizophre-
nia. Schizophr Res. 2000;46:209–215.
51. Wechsler D. The Wechsler Test of Adult Reading (WTAR).
San Antonio, TX: The Psychological Corporation; 2001.
52. Lezak MD. Neuropsychological assessment. New York:
Oxford University Press; 2004.
53. Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW.
Planning and spatial working memory following frontal lobe
lesions in man. Neuropsychologia. 1990;28:1021–1034.
54. van Winkel R, Myin-Germeys I, Delespaul P, et al. Premor-
bid IQ as a predictor for the course of IQ in first onset
patients with schizophrenia: a 10-year follow-up study.
Schizophr Res. 2006;88:47–54.
55. Cahn W, van Haren NEM, Pol HEH, et al. Brain volume
changes in the first year of illness and 5-year outcome of
schizophrenia. Br J Psychiatr. 2006;189:381–382.
56. Yung AR, Killackey E, Hetrick SE, et al. The prevention of
schizophrenia. Int Rev Psychiatr. 2007;19:633–646.
57. Lieberman JA, Buckley PF, Perkins DO. Neuroprotection:
a new strategy in the treatment of schizophrenia. CNS
Spectrums. 2007;12(10 suppl 18):1–16.
58. Cohen JD, Insel TR. Cognitive neuroscience and schizophre-
nia: translational research in need of a translator. Biol
Psychiatr. 2008;64:2–3.
59. Leeson VC, Robbins TW, Franklin C, et al. Dissociation of
long term verbal memory and fronto-executive impairment
in first-episode psychosis. Psychol Med. 2009;39:1799–1808.
60. Crawford JR, Parker DM, Stewart L. Prediction of WAIS IQ
with the National Adult Reading Test; cross validation and
extension. Br J Clin Psychol. 1989;28:267–273.
61. Crawford JR, Deary IJ, Starr J, Whalley JL. The NART as
an index of prior intellectual functioning: a retrospective
validity study covering a 66-year interval. Psychol Med.
2001;31:451–458.
62. Nelson HE, O’Connell A. Dementia: the estimation of pre-
morbid intelligence levels using the new adult reading test.
Cortex. 1978;14:234–244.
63. O’Carroll R. The assessment of pre-morbid ability. A critical
review. Neurocase. 1995;1:83–89.
64. O’Carroll R, Walker M, Duncan J. Selecting controls for
schizophrenia research studies: the use of the National Adult
Reading Test (NART) as a measure of pre-morbid ability.
Schizophr Res. 1992;8:137–141.
65. Crawford JR, Besson JA, Bremner M, et al. Estimation of
premorbid intelligence in schizophrenia. Br J Psychiatr.
1992;161:69–74.
66. Morrison G, Sharkey V, Allardyce J. Nithsdale schizophrenia
surveys: a longitudinal study of National Adult Reading Test
stability. Psychol Med. 2000;30:717–720.
67. Smith D, Roberts S, Brewer W, Pantelis C. Test-retest
reliability of the National Adult Reading Test (NART) as
an estimate of premorbid IQ in patients with schizophrenia.
Cognit Neuropsychiatry. 1998;3:71–80.
68. Barber F, Pantelis C, Bodger S, Nelson HE. Intellectual
functioning in schizophrenia: natural History. Chichester,
UK: John Wiley; 1996.
69. Eberhard J, Riley F, Levander S. Premorbid IQ and
schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2003;253:
84–88.
70. Russell AJ, Munro J, Jones P, et al. The National Adult
Reading Test as a measure of premorbid IQ in schizophrenia.
Br J Clin Psychol. 2000;39:297–305.
777
IQ Trajectory in First-Episode Psychosis